Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ALKS – Alkermes plc

ALKS — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

12.62

Margin Of Safety %

11

Put/Call OI Ratio

1.1

EPS Next Q Diff

0.3

EPS Last/This Y

0.88

EPS This/Next Y

-0.36

Price

33.03

Target Price

43.47

Analyst Recom

1.41

Performance Q

17.93

Upside

51.6%

Beta

0.39

Ticker: ALKS




16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09ALKS28.441.2912.356999
2026-03-10ALKS27.741.313.947440
2026-03-11ALKS27.761.340.047634
2026-03-12ALKS27.661.231.007921
2026-03-13ALKS27.641.231.007921
2026-03-17ALKS27.671.150.188287
2026-03-18ALKS27.21.081.208498
2026-03-20ALKS28.171.081.448565
2026-03-25ALKS29.381.190.895451
2026-03-26ALKS29.931.170.085507
2026-03-27ALKS29.41.140.165601
2026-03-30ALKS30.141.130.045632
2026-03-31ALKS35.381.040.205891
2026-04-01ALKS35.030.751.057873
2026-04-06ALKS34.091.005.669231
2026-04-07ALKS32.941.100.979727
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09ALKS28.45-26.920.62.35
2026-03-10ALKS27.73-26.913.62.35
2026-03-11ALKS27.76-26.923.02.35
2026-03-12ALKS27.66-26.921.22.35
2026-03-13ALKS27.77-26.924.52.35
2026-03-17ALKS27.66-26.918.32.35
2026-03-18ALKS27.21-26.916.82.35
2026-03-19ALKS28.41-26.980.62.35
2026-03-20ALKS28.15-26.976.82.35
2026-03-23ALKS27.69-26.969.82.35
2026-03-24ALKS28.41-26.980.72.35
2026-03-25ALKS29.36-26.995.22.35
2026-03-26ALKS29.93-26.9103.82.35
2026-03-27ALKS29.41-26.995.92.35
2026-03-30ALKS30.14-26.9106.92.35
2026-03-31ALKS35.37-26.9186.42.35
2026-04-01ALKS35.04-26.9181.52.35
2026-04-02ALKS34.83-26.9178.32.35
2026-04-06ALKS34.08-26.9166.92.35
2026-04-07ALKS33.03-26.9162.22.35
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09ALKS-3.743.6110.91
2026-03-10ALKS-3.743.6110.91
2026-03-11ALKS-3.743.6111.14
2026-03-12ALKS-3.743.6111.14
2026-03-13ALKS-3.743.6111.14
2026-03-18ALKS-3.743.6111.14
2026-03-19ALKS-3.743.6111.14
2026-03-20ALKS-3.743.6111.14
2026-03-23ALKS-3.743.6011.14
2026-03-24ALKS-3.743.6011.14
2026-03-25ALKS-3.743.6012.62
2026-03-26ALKS-3.743.6012.62
2026-03-27ALKS-3.743.6012.62
2026-03-30ALKS-3.743.6112.62
2026-03-31ALKS-3.743.6112.62
2026-04-01ALKS-3.743.6112.62
2026-04-02ALKS-3.993.6112.62
2026-04-06ALKS-3.993.6112.62
2026-04-07ALKS-4.053.6112.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.34

Avg. EPS Est. Current Quarter

0.21

Avg. EPS Est. Next Quarter

0.64

Insider Transactions

-4.05

Institutional Transactions

3.61

Beta

0.39

Average Sales Estimate Current Quarter

360

Average Sales Estimate Next Quarter

461

Fair Value

36.8

Quality Score

98

Growth Score

55

Sentiment Score

77

Actual DrawDown %

9.4

Max Drawdown 5-Year %

-33.2

Target Price

43.47

P/E

23.05

Forward P/E

45.16

PEG

P/S

3.73

P/B

3.01

P/Free Cash Flow

11.46

EPS

1.43

Average EPS Est. Cur. Y​

2.35

EPS Next Y. (Est.)

1.99

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

16.37

Relative Volume

0.86

Return on Equity vs Sector %

-14.2

Return on Equity vs Industry %

6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.41

EBIT Estimation

162.2
ALKS Healthcare
$33.02
📉
Swing / Pullback
Buy the dip on strong trends
27 /100
WEAK
Trend
0/20
Pullback
2/25
Volume
4/15
Valuation
16/20
TP/AR
2/10
Options
3/10
RSI
59.8
Range 1M
63.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
24 /100
WEAK
Momentum
2/25
Growth
10/30
Estimates
4/20
Inst/Vol
7/15
Options
1/10
EPS Yr
-133.6%
EPS NY
252.2%
52W%
69.2%
💎
Long-Term Value
Quality companies, undervalued
52 /100
WEAK
🟢 BUY +65.2% upside
Quality
19/30
Valuation
18/30
Growth
6/25
Stability
8/10
LT Trend
1/5
Upside
+65.2%
Quality
98
MoS
11%
Alkermes plc
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 2050
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS

Latest News

Caricamento notizie per ALKS
stock quote shares ALKS – Alkermes plc Stock Price stock today
news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALKS – Alkermes plc yahoo finance google finance
stock history ALKS – Alkermes plc invest stock market
stock prices ALKS premarket after hours
ticker ALKS fair value insiders trading